Mizuho On Atara Biotherapeutics – Distinguish Between Small Numbers And Science Failure
Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped…